The underestimated impact of cachexia

Jochen Springer, Stefan D. Anker

Research output: Contribution to journalArticle

Abstract

This editorial contains views on the importance of animal research in the field of cachexia, a crippling syndrome associated with almost all chronic diseases that dramatically impact on quality of life and survival of the patient. Unfortunately, it is infrequently identified or diagnosed and too rarely treated. Even if treated, the treatment options are extremely limited, as no truly successful therapies have been established so far. Therefore, research in animal models is of outmost importance, but care should be taken in designing these pre-clinical studies. We propose a design as close to clinical trials as possibly and to use primary endpoints that are of clinical relevance.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalExpert Opinion on Drug Discovery
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Cachexia
Chronic Disease
Animal Models
Quality of Life
Clinical Trials
Survival
Therapeutics
Research
Clinical Studies

Keywords

  • Wasting

ASJC Scopus subject areas

  • Drug Discovery

Cite this

The underestimated impact of cachexia. / Springer, Jochen; Anker, Stefan D.

In: Expert Opinion on Drug Discovery, Vol. 5, No. 1, 01.2010, p. 1-3.

Research output: Contribution to journalArticle

Springer, Jochen ; Anker, Stefan D. / The underestimated impact of cachexia. In: Expert Opinion on Drug Discovery. 2010 ; Vol. 5, No. 1. pp. 1-3.
@article{b540a60ed09940419273009f72762b08,
title = "The underestimated impact of cachexia",
abstract = "This editorial contains views on the importance of animal research in the field of cachexia, a crippling syndrome associated with almost all chronic diseases that dramatically impact on quality of life and survival of the patient. Unfortunately, it is infrequently identified or diagnosed and too rarely treated. Even if treated, the treatment options are extremely limited, as no truly successful therapies have been established so far. Therefore, research in animal models is of outmost importance, but care should be taken in designing these pre-clinical studies. We propose a design as close to clinical trials as possibly and to use primary endpoints that are of clinical relevance.",
keywords = "Wasting",
author = "Jochen Springer and Anker, {Stefan D.}",
year = "2010",
month = "1",
doi = "10.1517/17460440903483150",
language = "English",
volume = "5",
pages = "1--3",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The underestimated impact of cachexia

AU - Springer, Jochen

AU - Anker, Stefan D.

PY - 2010/1

Y1 - 2010/1

N2 - This editorial contains views on the importance of animal research in the field of cachexia, a crippling syndrome associated with almost all chronic diseases that dramatically impact on quality of life and survival of the patient. Unfortunately, it is infrequently identified or diagnosed and too rarely treated. Even if treated, the treatment options are extremely limited, as no truly successful therapies have been established so far. Therefore, research in animal models is of outmost importance, but care should be taken in designing these pre-clinical studies. We propose a design as close to clinical trials as possibly and to use primary endpoints that are of clinical relevance.

AB - This editorial contains views on the importance of animal research in the field of cachexia, a crippling syndrome associated with almost all chronic diseases that dramatically impact on quality of life and survival of the patient. Unfortunately, it is infrequently identified or diagnosed and too rarely treated. Even if treated, the treatment options are extremely limited, as no truly successful therapies have been established so far. Therefore, research in animal models is of outmost importance, but care should be taken in designing these pre-clinical studies. We propose a design as close to clinical trials as possibly and to use primary endpoints that are of clinical relevance.

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=73649103771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649103771&partnerID=8YFLogxK

U2 - 10.1517/17460440903483150

DO - 10.1517/17460440903483150

M3 - Article

C2 - 22823967

AN - SCOPUS:73649103771

VL - 5

SP - 1

EP - 3

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 1

ER -